Inactive Instrument

Pfenex Inc.

Equities

PFNX

US7170711045

Biotechnology & Medical Research

Pfenex Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 08, 2020 at 01:48 am IST

Pfenex Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced total revenue was USD 682,000 compared to USD 7.862 million a year ago. Operating loss was USD 10.201 million compared to USD 6.127 million a year ago. Net loss was USD 10.151 million compared to USD 6.058 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.19 a year ago.

Latest news about Pfenex Inc.

Pfenex Inc.(AMEX:PFNX) dropped from S&P TMI Index	30/20/30	CI
Pfenex Inc.(AMEX:PFNX) dropped from S&P Global BMI Index	30/20/30	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 3000 Growth Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Small Cap Comp Growth Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 3000 Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Growth Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Growth Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Small Cap Completeness Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Growth-Dynamic Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Dynamic Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Growth-Dynamic Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Microcap Growth Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Microcap Index	29/20/29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Dynamic Index	29/20/29	CI
Ligand Pharmaceuticals Incorporated completed the acquisition of Pfenex Inc..	29/20/29	CI
Ligand Pharmaceuticals Incorporated signed a definitive agreement to acquire Pfenex Inc. for approximately $460 million.	10/20/10	CI
Transcript : Pfenex Inc., Q2 2020 Earnings Call, Aug 06, 2020	07/20/07
Pfenex Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	07/20/07	CI
Pfenex Inc. Announces Positive European CHMP Opinion for Pf708 and New Partnership in Latin America, and Provides Crm197 Business Update	26/20/26	CI
Pfenex Inc. Announces U.S. Commercial Launch of Teriparatide Injection	12/20/12	CI
Transcript : Pfenex Inc. - Shareholder/Analyst Call	09/20/09
Transcript : Pfenex Inc., Q1 2020 Earnings Call, May 07, 2020	08/20/08
Pfenex Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	08/20/08	CI

Chart Pfenex Inc.

Duration

Period

More charts

Company Profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	11TCr
REGENERON PHARMACEUTICALS, INC.	+12.41%	11TCr
ARGENX SE	-2.59%	2.2TCr
BIONTECH SE	-12.38%	2.19TCr
GENMAB A/S	-5.29%	1.92TCr
BEIGENE, LTD.	-3.35%	1.81TCr
WUXI APPTEC CO., LTD.	-38.57%	1.77TCr
NEUROCRINE BIOSCIENCES, INC.	+7.51%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+35.67%	1.24TCr

Bio Therapeutic Drugs